Early disruptions in hepatic gene and protein expression exist prior to overt disease onset in both Pcyt2 + /- mice [15,16,24], and humans [42], yet the molecular mechanism underpinning the initiation, progression and heterogenous outcomes of NASH are unresolved. Here, PCYT2 is linked to metabolic dysfunction-associated steatohepatitis.